Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
Identifieur interne : 001B62 ( Main/Exploration ); précédent : 001B61; suivant : 001B63Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
Auteurs : Aswin Somasundaram [États-Unis] ; Mark A. Socinski ; Timothy F. BurnsSource :
- Expert opinion on pharmacotherapy [ 1744-7666 ] ; 2014.
Descripteurs français
- KwdFr :
- Antinéoplasiques (usage thérapeutique), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Humains, Inhibiteurs de protéines kinases (usage thérapeutique), Médecine individualisée, Pyrazoles (usage thérapeutique), Pyridines (usage thérapeutique), Récepteur du facteur de croissance épidermique (antagonistes et inhibiteurs), Récepteur du facteur de croissance épidermique (génétique), Récepteur du facteur de croissance épidermique (métabolisme), Récepteurs à activité tyrosine kinase (métabolisme), Résistance aux médicaments antinéoplasiques, Tumeurs du poumon (traitement médicamenteux).
- MESH :
- antagonistes et inhibiteurs : Récepteur du facteur de croissance épidermique.
- génétique : Récepteur du facteur de croissance épidermique.
- métabolisme : Récepteur du facteur de croissance épidermique, Récepteurs à activité tyrosine kinase.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs de protéines kinases, Pyrazoles, Pyridines.
- Humains, Médecine individualisée, Résistance aux médicaments antinéoplasiques.
English descriptors
- KwdEn :
- Antineoplastic Agents (therapeutic use), Carcinoma, Non-Small-Cell Lung (drug therapy), Drug Resistance, Neoplasm, Humans, Lung Neoplasms (drug therapy), Precision Medicine, Protein Kinase Inhibitors (therapeutic use), Pyrazoles (therapeutic use), Pyridines (therapeutic use), Receptor Protein-Tyrosine Kinases (metabolism), Receptor, Epidermal Growth Factor (antagonists & inhibitors), Receptor, Epidermal Growth Factor (genetics), Receptor, Epidermal Growth Factor (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Receptor, Epidermal Growth Factor.
- chemical , genetics : Receptor, Epidermal Growth Factor.
- chemical , metabolism : Receptor Protein-Tyrosine Kinases, Receptor, Epidermal Growth Factor.
- chemical , therapeutic use : Antineoplastic Agents, Protein Kinase Inhibitors, Pyrazoles, Pyridines.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- Drug Resistance, Neoplasm, Humans, Precision Medicine.
Abstract
The epidermal growth factor receptor (EGFR) is mutated in 15% of adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered in 8% of adenocarcinomas of the lung. Treatment of EGFR mutant and ALK translocation-positive tumors in NSCLC with tyrosine kinase inhibitors (TKI) results in a dramatic therapeutic response and has revolutionized therapy. Unfortunately, resistance to TKIs invariably develops. Many promising new therapies are under investigation to overcome the resistance.
DOI: 10.1517/14656566.2014.971013
PubMed: 25381900
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000E65
- to stream PubMed, to step Curation: 000E62
- to stream PubMed, to step Checkpoint: 000E62
- to stream Ncbi, to step Merge: 003D60
- to stream Ncbi, to step Curation: 003D60
- to stream Ncbi, to step Checkpoint: 003D60
- to stream Main, to step Merge: 001C33
- to stream Main, to step Curation: 001B62
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.</title><author><name sortKey="Somasundaram, Aswin" sort="Somasundaram, Aswin" uniqKey="Somasundaram A" first="Aswin" last="Somasundaram">Aswin Somasundaram</name><affiliation wicri:level="2"><nlm:affiliation>Lung Cancer Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lung Cancer Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Socinski, Mark A" sort="Socinski, Mark A" uniqKey="Socinski M" first="Mark A" last="Socinski">Mark A. Socinski</name></author><author><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25381900</idno><idno type="pmid">25381900</idno><idno type="doi">10.1517/14656566.2014.971013</idno><idno type="wicri:Area/PubMed/Corpus">000E65</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E65</idno><idno type="wicri:Area/PubMed/Curation">000E62</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E62</idno><idno type="wicri:Area/PubMed/Checkpoint">000E62</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E62</idno><idno type="wicri:Area/Ncbi/Merge">003D60</idno><idno type="wicri:Area/Ncbi/Curation">003D60</idno><idno type="wicri:Area/Ncbi/Checkpoint">003D60</idno><idno type="wicri:Area/Main/Merge">001C33</idno><idno type="wicri:Area/Main/Curation">001B62</idno><idno type="wicri:Area/Main/Exploration">001B62</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.</title><author><name sortKey="Somasundaram, Aswin" sort="Somasundaram, Aswin" uniqKey="Somasundaram A" first="Aswin" last="Somasundaram">Aswin Somasundaram</name><affiliation wicri:level="2"><nlm:affiliation>Lung Cancer Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lung Cancer Program, University of Pittsburgh Cancer Institute , Pittsburgh, PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Socinski, Mark A" sort="Socinski, Mark A" uniqKey="Socinski M" first="Mark A" last="Socinski">Mark A. Socinski</name></author><author><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="eISSN">1744-7666</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (therapeutic use)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Drug Resistance, Neoplasm</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Precision Medicine</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (therapeutic use)</term><term>Pyridines (therapeutic use)</term><term>Receptor Protein-Tyrosine Kinases (metabolism)</term><term>Receptor, Epidermal Growth Factor (antagonists & inhibitors)</term><term>Receptor, Epidermal Growth Factor (genetics)</term><term>Receptor, Epidermal Growth Factor (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (usage thérapeutique)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Humains</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Médecine individualisée</term><term>Pyrazoles (usage thérapeutique)</term><term>Pyridines (usage thérapeutique)</term><term>Récepteur du facteur de croissance épidermique (antagonistes et inhibiteurs)</term><term>Récepteur du facteur de croissance épidermique (génétique)</term><term>Récepteur du facteur de croissance épidermique (métabolisme)</term><term>Récepteurs à activité tyrosine kinase (métabolisme)</term><term>Résistance aux médicaments antinéoplasiques</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, Epidermal Growth Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptor, Epidermal Growth Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptor Protein-Tyrosine Kinases</term><term>Receptor, Epidermal Growth Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur du facteur de croissance épidermique</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Récepteur du facteur de croissance épidermique</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteur du facteur de croissance épidermique</term><term>Récepteurs à activité tyrosine kinase</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Inhibiteurs de protéines kinases</term><term>Pyrazoles</term><term>Pyridines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance, Neoplasm</term><term>Humans</term><term>Precision Medicine</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Médecine individualisée</term><term>Résistance aux médicaments antinéoplasiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The epidermal growth factor receptor (EGFR) is mutated in 15% of adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered in 8% of adenocarcinomas of the lung. Treatment of EGFR mutant and ALK translocation-positive tumors in NSCLC with tyrosine kinase inhibitors (TKI) results in a dramatic therapeutic response and has revolutionized therapy. Unfortunately, resistance to TKIs invariably develops. Many promising new therapies are under investigation to overcome the resistance.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><noCountry><name sortKey="Burns, Timothy F" sort="Burns, Timothy F" uniqKey="Burns T" first="Timothy F" last="Burns">Timothy F. Burns</name><name sortKey="Socinski, Mark A" sort="Socinski, Mark A" uniqKey="Socinski M" first="Mark A" last="Socinski">Mark A. Socinski</name></noCountry><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Somasundaram, Aswin" sort="Somasundaram, Aswin" uniqKey="Somasundaram A" first="Aswin" last="Somasundaram">Aswin Somasundaram</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25381900
|texte= Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25381900" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |